PCN162 Disease Burden of Castration-Resistant Prostate Cancer (CRPC) in China

Abstract

In China and even in the Asia Pacific region, study quantified the disease burden of NM-CRPC is lacking. This study aims to evaluate the disease burden (including epidemiology, survival, direct and indirect cost) of CRPC patients (including NN-CRPC and mCRPC) from the society perspective. First of all, to design the questionnaire, a systematic literature review on the CRPC’s epidemiology, economic burden and quality of life (QoL) was conducted. Furthermore, one-to-one web-meeting among 35 clinical experts specialized in urological diseases was conducted to collect relevant epidemiological, survival and costs information based on the pre-designed questionnaire. CRPC economic burden model was developed using Microsoft Excel 2013, and one-way sensitivity analysis was performed. Finally, Delphi panel meetings were organized to discuss the disease burden results. A total of 35 urologists from 33 class-3A hospitals in 21 cities participated in the questionnaire survey, 34 questionnaire results were eligible. In China, mCRPC accounts for a large proportion in CRPC (88.5%), and the diagnosed rate of NM-CRPC is low (39.3%). In current treatments, the metastasis-free survival (MFS) of NM-CRPC is only 13.3 months. The average total annual cost per NM-CRPC patient and per mCRPC patient were 69,145 CNY and 223,738 CNY respectively, with annual direct medical cost of 48,815 CNY and 171,082 CNY respectively. Sensitivity analysis results indicate that the direct medical costs per outpatient visit and the annual number of outpatient visits are the top two factors which impact the results. In China, NM-CRPC is associated with poor diagnosed rate and low metastasis-free survival. NM-CRPC imposes heavy economic burden, and mCRPC is more serious. This study highlights the critical need to introduce innovative therapies with better clinical efficacy with the delay in metastatic progression, to extend survival and improve QoL, and to reduce total cost and hospitalization admission for CRPC patients in China.